Published in Expert Rev Mol Diagn on March 01, 2008
From transcriptome analysis to therapeutic anti-CD40L treatment in the SOD1 model of amyotrophic lateral sclerosis. Nat Genet (2010) 1.32
GWAS meets microarray: are the results of genome-wide association studies and gene-expression profiling consistent? Prostate cancer as an example. PLoS One (2009) 1.20
Microarray analysis of cutaneous squamous cell carcinomas reveals enhanced expression of epidermal differentiation complex genes. Mol Carcinog (2010) 1.08
Integrating contextual miRNA and protein signatures for diagnostic and treatment decisions in cancer. Expert Rev Mol Diagn (2011) 0.97
Impact of collection and storage of lung tumor tissue on whole genome expression profiling. J Mol Diagn (2012) 0.88
Incorporating network structure in integrative analysis of cancer prognosis data. Genet Epidemiol (2012) 0.87
Gene expression profile of peripheral blood lymphocytes from renal cell carcinoma patients treated with IL-2, interferon-α and dendritic cell vaccine. PLoS One (2012) 0.86
In vitro and in vivo antitumor activity of a novel pH-activated polymeric drug delivery system for doxorubicin. PLoS One (2012) 0.85
Epithelial-mesenchymal transition-associated secretory phenotype predicts survival in lung cancer patients. Carcinogenesis (2014) 0.84
Smoking-Related Gene Expression in Laser Capture-Microdissected Human Lung. Clin Cancer Res (2009) 0.82
Bronchial airway gene expression in smokers with lung or head and neck cancer. Cancer Med (2014) 0.76
Consensus of gene expression phenotypes and prognostic risk predictors in primary lung adenocarcinoma. Oncotarget (2016) 0.75
AURKA mRNA expression is an independent predictor of poor prognosis in patients with non-small cell lung cancer. Oncol Lett (2017) 0.75
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med (2006) 10.48
Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med (2015) 10.12
Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med (2015) 6.28
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28
Management of non-small-cell lung cancer: recent developments. Lancet (2013) 3.51
Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol (2010) 3.40
Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med (2011) 3.03
Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol (2005) 2.85
Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res (2006) 2.84
The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol (2010) 2.64
Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA (2004) 2.47
Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. J Clin Oncol (2013) 2.44
ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med (2013) 2.38
Nonapoptotic role for Apaf-1 in the DNA damage checkpoint. Mol Cell (2007) 2.20
Aquaporin 1 is overexpressed in lung cancer and stimulates NIH-3T3 cell proliferation and anchorage-independent growth. Am J Pathol (2006) 2.19
Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol (2009) 2.16
Cyclophosphamide induces differentiation of Th17 cells in cancer patients. Cancer Res (2010) 2.12
Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials. Clin Cancer Res (2013) 2.06
Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. Clin Cancer Res (2012) 1.95
IFCT-0401 Trial: a phase II study of gefitinib administered as first-line treatment in advanced adenocarcinoma with bronchioloalveolar carcinoma subtype. J Thorac Oncol (2009) 1.72
Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer. J Clin Oncol (2013) 1.71
Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol (2013) 1.66
Reversing resistance to vascular-disrupting agents by blocking late mobilization of circulating endothelial progenitor cells. Cancer Discov (2012) 1.63
Erythropoietin and erythropoietin receptor coexpression is associated with poor survival in stage I non-small cell lung cancer. Clin Cancer Res (2007) 1.59
Human telomerase reverse transcriptase (hTERT) and Ki-67 are better predictors of survival than established clinical indicators in patients undergoing curative hepatic resection for colorectal metastases. Ann Surg Oncol (2004) 1.58
Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res (2013) 1.58
Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol (2010) 1.52
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin Cancer Res (2011) 1.52
Cyclooxygenase-2 as a target for anticancer drug development. Crit Rev Oncol Hematol (2006) 1.51
Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities? J Clin Oncol (2011) 1.48
Involvement of aquaporins in colorectal carcinogenesis. Oncogene (2003) 1.45
Prognostic impact of vitamin B6 metabolism in lung cancer. Cell Rep (2012) 1.45
Telomerase expression in lung preneoplasia and neoplasia. Int J Cancer (2007) 1.45
Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer. Clin Lung Cancer (2012) 1.40
First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. Clin Cancer Res (2012) 1.39
Molecular circuits of solid tumors: prognostic and predictive tools for bedside use. Nat Rev Clin Oncol (2010) 1.36
Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors. J Clin Oncol (2012) 1.33
Are RAS mutations predictive markers of resistance to standard chemotherapy? Nat Rev Clin Oncol (2009) 1.32
Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers. J Clin Oncol (2004) 1.25
ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer. Curr Opin Pulm Med (2007) 1.24
The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. Nat Rev Clin Oncol (2012) 1.23
ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development. Eur J Cancer (2012) 1.22
Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour. Invest New Drugs (2009) 1.20
ERCC1 and RRM1: ready for prime time? J Clin Oncol (2013) 1.17
Aquaporin expression in human lymphocytes and dendritic cells. Am J Hematol (2004) 1.17
Tumor assessment criteria in phase I trials: beyond RECIST. J Clin Oncol (2012) 1.15
Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites. J Thorac Oncol (2009) 1.15
Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol (2011) 1.14
Telomere length, telomeric proteins and genomic instability during the multistep carcinogenic process. Crit Rev Oncol Hematol (2008) 1.12
Cisplatin resistance associated with PARP hyperactivation. Cancer Res (2013) 1.11
Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC. Clin Cancer Res (2011) 1.08
Inclusion of patients with advanced cancer in phase I trials: is this a tool for improving optimism and emotional well-being? J Clin Oncol (2013) 1.08
Discrepancies between primary tumor and metastasis: a literature review on clinically established biomarkers. Crit Rev Oncol Hematol (2012) 1.06
Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Clin Cancer Res (2013) 1.05
Differential immunohistochemical and biological profile of squamous cell carcinoma of the breast. Anticancer Res (2007) 1.05
Tumour molecular profiling for deciding therapy-the French initiative. Nat Rev Clin Oncol (2012) 1.04
Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program. J Clin Oncol (2007) 1.04
hTERT expression is a prognostic factor of survival in patients with stage I non-small cell lung cancer. Clin Cancer Res (2002) 1.04
ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis. Am J Pathol (2010) 1.04
NK cells infiltrating a MHC class I-deficient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK cell-triggering receptors. J Immunol (2005) 1.01
Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies. Eur J Cancer (2013) 1.01
Lung cancer mortality risk among breast cancer patients treated with anti-estrogens. Cancer (2011) 1.00
Loss-of-function alleles of P2RX7 and TLR4 fail to affect the response to chemotherapy in non-small cell lung cancer. Oncoimmunology (2012) 1.00
Uncertain benefit from surgery in patients with lung metastases from breast carcinoma. Cancer (2004) 1.00
Tumour growth rates and RECIST criteria in early drug development. Eur J Cancer (2011) 1.00
MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer. Clin Cancer Res (2010) 1.00
Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study. J Thorac Oncol (2015) 0.99
Integrated molecular portrait of non-small cell lung cancers. BMC Med Genomics (2013) 0.99
Mechanisms of Disease: signal transduction in lung carcinogenesis -- a comparison of smokers and never-smokers. Nat Clin Pract Oncol (2008) 0.99
Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program. Clin Cancer Res (2007) 0.99
Association of a functional tandem repeats in the downstream of human telomerase gene and lung cancer. Oncogene (2003) 0.99
Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (Everolimus) in combination. Mol Cancer Ther (2010) 0.98
Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC. J Thorac Oncol (2014) 0.98
Targeting the deregulated spliceosome core machinery in cancer cells triggers mTOR blockade and autophagy. Cancer Res (2013) 0.98
Type 1 plasminogen activator inhibitor deficiency aggravates the course of experimental glomerulonephritis through overactivation of transforming growth factor beta. FASEB J (2003) 0.98
Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease. Cochrane Database Syst Rev (2007) 0.98
The genetic complexity of common cancers and the promise of personalized medicine: is there any hope? J Pathol (2014) 0.97
A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy. Breast Cancer Res Treat (2013) 0.97
Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nat Clin Pract Oncol (2008) 0.97
Biology-driven phase II trials: what is the optimal model for molecular selection? J Clin Oncol (2011) 0.96
Breast metastasis from lung adenocarcinoma: a case report. Anticancer Res (2003) 0.96
Implications of personalized medicine--perspective from a cancer center. Nat Rev Clin Oncol (2011) 0.96
Customized adjuvant phase II trial in patients with non-small-cell lung cancer: IFCT-0801 TASTE. J Clin Oncol (2014) 0.96
Histopathologic and genetic alterations as predictors of response to treatment and survival in lung cancer: a review of published data. Crit Rev Oncol Hematol (2009) 0.96
Circulating tumor cells in lung cancer. Acta Cytol (2012) 0.95
PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs. Lung Cancer (2013) 0.95
Mitogen-activated protein kinase activation in lung adenocarcinoma: a comparative study between ever smokers and never smokers. Clin Cancer Res (2008) 0.95
ERCC1-tailored chemotherapy in lung cancer: the first prospective randomized trial. J Clin Oncol (2007) 0.95
p38 Mitogen-activated protein kinase signaling, ERCC1 expression, and viability of lung cancer cells from never or light smoker patients. Cancer (2012) 0.95
Differential expression of biomarkers in men and women. Semin Oncol (2009) 0.94
Portrait of ependymoma recurrence in children: biomarkers of tumor progression identified by dual-color microarray-based gene expression analysis. PLoS One (2010) 0.94
Maintenance therapy and advanced non-small-cell lung cancer: a skeptic's view. J Thorac Oncol (2012) 0.94
Targeted therapy-induced radiation recall. Eur J Cancer (2013) 0.94
Expression of erythropoietin and erythropoietin receptor in non-small cell lung carcinomas. Clin Cancer Res (2005) 0.93
Bioluminescent orthotopic mouse models of human localized non-small cell lung cancer: feasibility and identification of circulating tumour cells. PLoS One (2011) 0.93